Indications for CAPLYTA:
Take with food. 42mg once daily.
Increased mortality in elderly patients with dementia-related psychosis.
Elderly with dementia-related psychosis (not approved use); increased risk of death or cerebrovascular events (eg, stroke, TIA). Discontinue immediately if neuroleptic malignant syndrome is suspected. Cardio- or cerebrovascular disease. Risk for hypotension, aspiration, seizures, or diabetes (do baseline fasting blood sugar). Pre-existing low WBC or ANC, or a history of leukopenia/neutropenia; monitor CBC during 1st few months of treatment; discontinue if WBC decline. Exposure to extreme heat. Dehydration. Hypovolemia. Perform fall risk assessments when initiating and recurrently on long-term therapy. Monitor for hyperglycemia, dyslipidemia, weight gain. Reevaluate periodically. Write ℞ for smallest practical amount. Moderate to severe hepatic impairment: not recommended. Neonates: risk for extrapyramidal and/or withdrawal symptoms post delivery (due to exposure during 3rd-trimester pregnancy). Pregnancy. Nursing mothers: not recommended.
Potentiated by moderate or strong CYP3A4 inhibitors (eg, amprenavir, ciprofloxacin, cyclosporine, diltiazem, erythromycin, fluconazole, fluvoxamine, verapamil, clarithromycin, grapefruit juice, itraconazole, voriconazole, nefazodone, ritonavir, nelfinavir); avoid. Antagonized by CYP3A4 inducers (eg, carbamazepine, phenytoin, rifampin, St. John’s wort, bosentan, efavirenz, etravirine, modafinil, nafcillin, aprepitant, armodafinil, pioglitazone, prednisone); avoid. May be potentiated by UGT inhibitors (eg, valproic acid, probenecid); avoid. Caution with drugs that interfere with temperature regulation (eg, anticholinergics).
Somnolence/sedation, dry mouth; tardive dyskinesia (consider discontinuation if occurs), neutropenia, orthostatic hypotension, syncope.
Register patients in the National Pregnancy Registry for Atypical Antipsychotics (866) 961-2388.